In Brief: Cardiometrics/Cordis
This article was originally published in The Gray Sheet
Executive Summary
Cardiometrics/Cordis: Ink distribution agreement under which Johnson & Johnson subsidiary Cordis gains U.S. distribution rights to Cardiometrics' FloWire doppler guide wire. The pact broadens an existing agreement for marketing of the device overseas. Cardiometrics says J&J's "strong distribution channels should enable faster market penetration" in the U.S. Under the deal, J&J also gains U.S. rights to Cardiometrics' WaveWire pressure guide wire products. Cardiometrics submitted a 510(k) for WaveWire in December 1996. Cardiometrics, which recently entered an agreement to be acquired by intravascular ultrasound catheter firm EndoSonics ("The Gray Sheet" Feb. 3, p. 9), will continue to market its FloWire and WaveWire products domestically to "40 key accounts" through the end of 1997. At year-end, J&J, EndoSonics, and Cardiometrics will negotiate terms for 1998...
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.